Search results
Showing 1456 to 1470 of 1516 results for patients and public
Discontinued Reference number: GID-TA10996
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]
Discontinued Reference number: GID-TA11004
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
In development Reference number: GID-TA10895 Expected publication date: 29 October 2026
In development Reference number: GID-TA11163 Expected publication date: TBC
Discontinued Reference number: GID-TA11005
Discontinued Reference number: GID-TA11318
In development Reference number: GID-TA11214 Expected publication date: TBC
Discontinued Reference number: GID-TA11007
Vosoritide for treating achondroplasia in people 4 months and over [ID6488]
In development Reference number: GID-TA11528 Expected publication date: TBC
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
In development Reference number: GID-TA11086 Expected publication date: TBC
In development Reference number: GID-TA11008 Expected publication date: TBC
This guideline covers the planning and management of end of life and palliative care for infants, children and young people (aged 0 to 17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.
Discontinued Reference number: GID-TAG387
This guideline covers the planning, delivery and review of social work interventions for adults who have complex needs. It promotes ways for social work professionals, other care staff and people with complex needs to work together to make decisions about care and support.